PHARMANUTRA SPA (PHN.MI) Fundamental Analysis & Valuation

BIT:PHN • IT0005274094

Current stock price

78.25 EUR
+2.25 (+2.96%)
Last:

This PHN.MI fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

8

1. PHN.MI Profitability Analysis

1.1 Basic Checks

  • In the past year PHN was profitable.
  • In the past year PHN had a positive cash flow from operations.
  • In the past 5 years PHN has always been profitable.
  • Each year in the past 5 years PHN had a positive operating cash flow.
PHN.MI Yearly Net Income VS EBIT VS OCF VS FCFPHN.MI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M 20M

1.2 Ratios

  • PHN has a Return On Assets of 20.17%. This is amongst the best in the industry. PHN outperforms 100.00% of its industry peers.
  • PHN has a better Return On Equity (36.55%) than 85.71% of its industry peers.
  • Looking at the Return On Invested Capital, with a value of 25.72%, PHN belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
  • The Average Return On Invested Capital over the past 3 years for PHN is significantly above the industry average of 11.49%.
  • The last Return On Invested Capital (25.72%) for PHN is above the 3 year average (17.21%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 20.17%
ROE 36.55%
ROIC 25.72%
ROA(3y)13.53%
ROA(5y)17.42%
ROE(3y)26.61%
ROE(5y)29.54%
ROIC(3y)17.21%
ROIC(5y)18.21%
PHN.MI Yearly ROA, ROE, ROICPHN.MI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 10 20 30 40 50

1.3 Margins

  • PHN has a Profit Margin of 13.39%. This is in the better half of the industry: PHN outperforms 64.29% of its industry peers.
  • In the last couple of years the Profit Margin of PHN has declined.
  • PHN has a better Operating Margin (21.79%) than 100.00% of its industry peers.
  • In the last couple of years the Operating Margin of PHN has remained more or less at the same level.
  • With an excellent Gross Margin value of 97.13%, PHN belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
  • PHN's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 21.79%
PM (TTM) 13.39%
GM 97.13%
OM growth 3Y-4.84%
OM growth 5Y1.01%
PM growth 3Y-10.74%
PM growth 5Y-1.82%
GM growth 3Y-0.75%
GM growth 5Y-0.04%
PHN.MI Yearly Profit, Operating, Gross MarginsPHN.MI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 20 40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. PHN.MI Health Analysis

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), PHN is creating value.
  • Compared to 1 year ago, PHN has about the same amount of shares outstanding.
  • PHN has less shares outstanding than it did 5 years ago.
  • PHN has a better debt/assets ratio than last year.
PHN.MI Yearly Shares OutstandingPHN.MI Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M
PHN.MI Yearly Total Debt VS Total AssetsPHN.MI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

  • An Altman-Z score of 12.01 indicates that PHN is not in any danger for bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 12.01, PHN belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
  • PHN has a debt to FCF ratio of 2.01. This is a good value and a sign of high solvency as PHN would need 2.01 years to pay back of all of its debts.
  • With a decent Debt to FCF ratio value of 2.01, PHN is doing good in the industry, outperforming 71.43% of the companies in the same industry.
  • PHN has a Debt/Equity ratio of 0.24. This is a healthy value indicating a solid balance between debt and equity.
  • With a decent Debt to Equity ratio value of 0.24, PHN is doing good in the industry, outperforming 64.29% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.24
Debt/FCF 2.01
Altman-Z 12.01
ROIC/WACC3.28
WACC7.85%
PHN.MI Yearly LT Debt VS Equity VS FCFPHN.MI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M 40M 60M

2.3 Liquidity

  • A Current Ratio of 2.19 indicates that PHN has no problem at all paying its short term obligations.
  • With an excellent Current ratio value of 2.19, PHN belongs to the best of the industry, outperforming 92.86% of the companies in the same industry.
  • PHN has a Quick Ratio of 1.86. This is a normal value and indicates that PHN is financially healthy and should not expect problems in meeting its short term obligations.
  • PHN has a Quick ratio of 1.86. This is amongst the best in the industry. PHN outperforms 92.86% of its industry peers.
Industry RankSector Rank
Current Ratio 2.19
Quick Ratio 1.86
PHN.MI Yearly Current Assets VS Current LiabilitesPHN.MI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. PHN.MI Growth Analysis

3.1 Past

  • PHN shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -14.74%.
  • The Earnings Per Share has been growing by 8.59% on average over the past years. This is quite good.
  • The Revenue has grown by 21.13% in the past year. This is a very strong growth!
  • PHN shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 16.51% yearly.
EPS 1Y (TTM)-14.74%
EPS 3Y-2.81%
EPS 5Y8.59%
EPS Q2Q%N/A
Revenue 1Y (TTM)21.13%
Revenue growth 3Y21.08%
Revenue growth 5Y16.51%
Sales Q2Q%-37.6%

3.2 Future

  • Based on estimates for the next years, PHN will show a very strong growth in Earnings Per Share. The EPS will grow by 23.20% on average per year.
  • The Revenue is expected to grow by 14.86% on average over the next years. This is quite good.
EPS Next Y43.02%
EPS Next 2Y23.44%
EPS Next 3Y23.44%
EPS Next 5Y23.2%
Revenue Next Year15.93%
Revenue Next 2Y15.61%
Revenue Next 3Y15.37%
Revenue Next 5Y14.86%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
PHN.MI Yearly Revenue VS EstimatesPHN.MI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 50M 100M 150M 200M 250M
PHN.MI Yearly EPS VS EstimatesPHN.MI Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2019 2020 2021 2022 2023 2024 2025 2026 2027 1 2 3

More info and screens

Find the best growth stocksShow best growing peers

2

4. PHN.MI Valuation Analysis

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 58.83, PHN can be considered very expensive at the moment.
  • 78.57% of the companies in the same industry are cheaper than PHN, based on the Price/Earnings ratio.
  • Compared to an average S&P500 Price/Earnings ratio of 24.75, PHN is valued quite expensively.
  • Based on the Price/Forward Earnings ratio of 38.61, the valuation of PHN can be described as expensive.
  • 85.71% of the companies in the same industry are cheaper than PHN, based on the Price/Forward Earnings ratio.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 22.10, PHN is valued quite expensively.
Industry RankSector Rank
PE 58.83
Fwd PE 38.61
PHN.MI Price Earnings VS Forward Price EarningsPHN.MI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40 50

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of PHN indicates a slightly more expensive valuation: PHN is more expensive than 78.57% of the companies listed in the same industry.
  • PHN's Price/Free Cash Flow ratio is rather expensive when compared to the industry. PHN is more expensive than 85.71% of the companies in the same industry.
Industry RankSector Rank
P/FCF 72.66
EV/EBITDA 16.96
PHN.MI Per share dataPHN.MI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15

4.3 Compensation for Growth

  • The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
  • PHN has an outstanding profitability rating, which may justify a higher PE ratio.
  • PHN's earnings are expected to grow with 23.44% in the coming years. This may justify a more expensive valuation.
PEG (NY)1.37
PEG (5Y)6.85
EPS Next 2Y23.44%
EPS Next 3Y23.44%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

4

5. PHN.MI Dividend Analysis

5.1 Amount

  • PHN has a Yearly Dividend Yield of 1.32%. Purely for dividend investing, there may be better candidates out there.
  • Compared to an average industry Dividend Yield of 2.48, PHN is paying slightly less dividend.
  • Compared to the average S&P500 Dividend Yield of 1.89, PHN is paying slightly less dividend.
Industry RankSector Rank
Dividend Yield 1.32%

5.2 History

  • On average, the dividend of PHN grows each year by 11.21%, which is quite nice.
Dividend Growth(5Y)11.21%
Div Incr Years0
Div Non Decr Years0

5.3 Sustainability

  • PHN pays out 39.70% of its income as dividend. This is a sustainable payout ratio.
  • The dividend of PHN is growing, but earnings are growing more, so the dividend growth is sustainable.
DP39.7%
EPS Next 2Y23.44%
EPS Next 3Y23.44%
PHN.MI Yearly Income VS Free CF VS DividendPHN.MI Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M -5M 10M 15M
PHN.MI Dividend Payout.PHN.MI Dividend Payout, showing the Payout Ratio.PHN.MI Dividend Payout.PayoutRetained Earnings

More info and screens

Find the best dividend stocksShow peers with best dividend

PHN.MI Fundamentals: All Metrics, Ratios and Statistics

PHARMANUTRA SPA

BIT:PHN (3/31/2026, 5:29:49 PM)

78.25

+2.25 (+2.96%)

Chartmill FA Rating
GICS SectorConsumer Staples
GICS IndustryGroupHousehold & Personal Products
GICS IndustryPersonal Care Products
Earnings (Last)03-17
Earnings (Next)05-11
Inst Owners15.64%
Inst Owner ChangeN/A
Ins Owners65.02%
Ins Owner ChangeN/A
Market Cap757.46M
Revenue(TTM)100.20M
Net Income(TTM)24.16M
Analysts82.86
Price Target88.74 (13.41%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 1.32%
Yearly Dividend0.85
Dividend Growth(5Y)11.21%
DP39.7%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)5.67%
PT rev (3m)7.41%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0.28%
EPS NY rev (3m)0.28%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)2.53%
Revenue NY rev (1m)0.31%
Revenue NY rev (3m)0.43%
Valuation
Industry RankSector Rank
PE 58.83
Fwd PE 38.61
P/S 4.2
P/FCF 72.66
P/OCF 52.42
P/B 11.46
P/tB 18.15
EV/EBITDA 16.96
EPS(TTM)1.33
EY1.7%
EPS(NY)2.03
Fwd EY2.59%
FCF(TTM)1.08
FCFY1.38%
OCF(TTM)1.49
OCFY1.91%
SpS18.64
BVpS6.83
TBVpS4.31
PEG (NY)1.37
PEG (5Y)6.85
Graham Number14.29
Profitability
Industry RankSector Rank
ROA 20.17%
ROE 36.55%
ROCE 44.34%
ROIC 25.72%
ROICexc 34.17%
ROICexgc 53.82%
OM 21.79%
PM (TTM) 13.39%
GM 97.13%
FCFM 5.78%
ROA(3y)13.53%
ROA(5y)17.42%
ROE(3y)26.61%
ROE(5y)29.54%
ROIC(3y)17.21%
ROIC(5y)18.21%
ROICexc(3y)25.61%
ROICexc(5y)33.67%
ROICexgc(3y)43.23%
ROICexgc(5y)50.61%
ROCE(3y)29.76%
ROCE(5y)31.61%
ROICexgc growth 3Y-15.98%
ROICexgc growth 5Y-10.26%
ROICexc growth 3Y-20.69%
ROICexc growth 5Y-11.75%
OM growth 3Y-4.84%
OM growth 5Y1.01%
PM growth 3Y-10.74%
PM growth 5Y-1.82%
GM growth 3Y-0.75%
GM growth 5Y-0.04%
F-Score7
Asset Turnover1.51
Health
Industry RankSector Rank
Debt/Equity 0.24
Debt/FCF 2.01
Debt/EBITDA 0.37
Cap/Depr 112.59%
Cap/Sales 2.23%
Interest Coverage 250
Cash Conversion 33.69%
Profit Quality 43.15%
Current Ratio 2.19
Quick Ratio 1.86
Altman-Z 12.01
F-Score7
WACC7.85%
ROIC/WACC3.28
Cap/Depr(3y)763.09%
Cap/Depr(5y)544.05%
Cap/Sales(3y)14.97%
Cap/Sales(5y)11.04%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-14.74%
EPS 3Y-2.81%
EPS 5Y8.59%
EPS Q2Q%N/A
EPS Next Y43.02%
EPS Next 2Y23.44%
EPS Next 3Y23.44%
EPS Next 5Y23.2%
Revenue 1Y (TTM)21.13%
Revenue growth 3Y21.08%
Revenue growth 5Y16.51%
Sales Q2Q%-37.6%
Revenue Next Year15.93%
Revenue Next 2Y15.61%
Revenue Next 3Y15.37%
Revenue Next 5Y14.86%
EBIT growth 1Y10.97%
EBIT growth 3Y13.47%
EBIT growth 5Y17.77%
EBIT Next Year22.37%
EBIT Next 3Y20.23%
EBIT Next 5Y14.04%
FCF growth 1Y164.53%
FCF growth 3Y1.75%
FCF growth 5Y17.94%
OCF growth 1Y18.84%
OCF growth 3Y0.14%
OCF growth 5Y11.34%

PHARMANUTRA SPA / PHN.MI Fundamental Analysis FAQ

What is the fundamental rating for PHN stock?

ChartMill assigns a fundamental rating of 7 / 10 to PHN.MI.


Can you provide the valuation status for PHARMANUTRA SPA?

ChartMill assigns a valuation rating of 2 / 10 to PHARMANUTRA SPA (PHN.MI). This can be considered as Overvalued.


What is the profitability of PHN stock?

PHARMANUTRA SPA (PHN.MI) has a profitability rating of 8 / 10.


How financially healthy is PHARMANUTRA SPA?

The financial health rating of PHARMANUTRA SPA (PHN.MI) is 8 / 10.


Is the dividend of PHARMANUTRA SPA sustainable?

The dividend rating of PHARMANUTRA SPA (PHN.MI) is 4 / 10 and the dividend payout ratio is 39.7%.